相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model
Y. Barnea et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study
Anouk E. Muller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Evaluation of Ceftobiprole Activity against a Variety of Gram-Negative Pathogens, Including Escherichia coli, Haemophilus influenzae (β-Lactamase Positive and β-Lactamase Negative), and Klebsiella pneumoniae, in a Rabbit Meningitis Model
A. Stucki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Ceftobiprole Efficacy In Vitro against Panton-Valentine Leukocidin Production and In Vivo against Community-Associated Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rabbits
Azzam Saleh-Mghir et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
C. Germel et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)
Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone
Todd A. Davies et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
Susan C. Nicholson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Structural Insights into the Anti-methicillin-resistant Staphylococcus aureus (MRSA) Activity of Ceftobiprole
Andrew L. Lovering et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Telavancin versus Vancomycin for HospitalAcquired Pneumonia due to Gram-positive Pathogens
Ethan Rubinstein et al.
CLINICAL INFECTIOUS DISEASES (2011)
In Vivo Activity of Ceftobiprole in Murine Skin Infections Due to Staphylococcus aureus and Pseudomonas aeruginosa
Jeffrey Fernandez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Ceftobiprole Is Superior to Vancomycin, Daptomycin, and Linezolid for Treatment of Experimental Endocarditis in Rabbits Caused by Methicillin-Resistant Staphylococcus aureus
P. Tattevin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Mortality, Attributable Mortality, and Clinical Events as End Points for Clinical Trials of Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia
John G. Muscedere et al.
CLINICAL INFECTIOUS DISEASES (2010)
Use of Severity Scoring and Stratification Factors in Clinical Trials of Hospital-Acquired and Ventilator-Associated Pneumonia
Lena M. Napolitano
CLINICAL INFECTIOUS DISEASES (2010)
Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia
Antoni Torres et al.
CLINICAL INFECTIOUS DISEASES (2010)
Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Ronald N. Jones
CLINICAL INFECTIOUS DISEASES (2010)
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Antonio T. Freire et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models
Moliere Nguile-Makao et al.
INTENSIVE CARE MEDICINE (2010)
Comparative in vitro activity of ceftobiprole against Gram-positive cocci
Carmen Betriu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Ceftobiprole - A review of a broad-spectrum and anti-MRSA cephalosporin
George G. Zhanel et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2008)
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections
Karen M. Amsler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus
Li-Yan Yin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia:: a randomized, open-label, multicenter study
Alvaro Rea-Neto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model
Cesar A. Arias et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae
Todd A. Davies et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The place of guidelines in hospital-acquired pneumonia
R. Masterton
JOURNAL OF HOSPITAL INFECTION (2007)
In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals
Olivier Denis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x
TA Davies et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin
T Bogdanovich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus
HF Chambers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
分享论文
